Valuation: Acrux Limited

Market Cap 6.16M 4.27M 3.74M 3.44M 3.19M 6.06M 405M 41.31M 16.06M 200M 16.04M 15.69M 692M P/E 2024
-3.44x
P/E 2025 -0.95x
Enterprise Value 8.93M 6.19M 5.42M 5M 4.63M 8.79M 588M 59.9M 23.29M 290M 23.25M 22.75M 1B EV / Sales 2024
4.09x
EV / Sales 2025 7.81x
Free-Float
78.27%
Yield 2024 *
-
Yield 2025 -
1 day-4.17%
1 week-11.54%
Current month-4.17%
1 month-4.17%
3 months+4.55%
6 months-23.33%
Current year-23.33%
1 week 0.01
Extreme 0.011
0.01
1 month 0.01
Extreme 0.011
0.02
Current year 0.01
Extreme 0.009
0.02
1 year 0.01
Extreme 0.009
0.02
3 years 0.01
Extreme 0.009
0.1
5 years 0.01
Extreme 0.009
0.14
10 years 0.01
Extreme 0.009
0.84
Manager TitleAgeSince
Chief Executive Officer - 01/06/2025
Director of Finance/CFO - 21/06/2021
Chief Tech/Sci/R&D Officer - 15/02/2015
Director TitleAgeSince
Chairman 74 01/01/2006
Director/Board Member - 01/10/2013
Director/Board Member 70 01/06/2016
Change 5-day change 1-year change 3-year change Capi.($)
-4.17%-11.54%-39.47%-79.09% 4.27M
-0.49%+1.53%+13.55%+82.58% 48.11B
-1.41%+5.55%+70.04%+116.16% 37.88B
-1.39%-0.16%-4.06%+42.16% 12.47B
+0.44%+2.83%+15.18%+96.06% 12B
+1.82%+2.76%+34.19%+120.25% 9.03B
-0.16%+1.91%+22.31%+47.95% 7.24B
+0.41%+2.01%+55.16%-3.74% 7.09B
-2.81%+17.66%-18.38%+20.93% 6.54B
-0.26%+3.58%+23.74%+238.93% 6.72B
Average -0.79%+2.98%+17.22%+68.22% 14.71B
Weighted average by Cap. -0.61%+3.97%+29.49%+89.75%

Financials

2024 2025
Net sales 5.09M 3.53M 3.09M 2.85M 2.64M 5.01M 335M 34.14M 13.28M 165M 13.26M 12.97M 572M 1.19M 825K 722K 666K 617K 1.17M 78.33M 7.98M 3.1M 38.66M 3.1M 3.03M 134M
Net income -5.8M -4.02M -3.52M -3.24M -3.01M -5.71M -382M -38.9M -15.13M -188M -15.1M -14.77M -651M -5.94M -4.12M -3.61M -3.33M -3.08M -5.85M -391M -39.87M -15.51M -193M -15.48M -15.14M -668M
Net Debt 759K 526K 461K 425K 393K 747K 49.96M 5.09M 1.98M 24.66M 1.98M 1.93M 85.22M 2.77M 1.92M 1.68M 1.55M 1.44M 2.73M 182M 18.59M 7.23M 90.05M 7.22M 7.06M 311M
Logo Acrux Limited
Acrux Limited is an Australia-based specialty pharmaceutical company. The Company is engaged in developing and commercializing a pipeline of topically applied pharmaceutical products. Its products include Lidocaine and Prilocaine Cream, USP 2.5%/2.5%, Lenzetto, Evamist, Dapsone Gel, 5% and Testosterone Topical Solution, 30 mg / 1.5 ml. Lidocaine and Prilocaine Cream USP (a eutectic mixture of lidocaine 2.5% and prilocaine 2.5%) is indicated as a topical anesthetic for use on normal intact skin for local analgesia and genital mucous membranes for superficial minor surgery and as pretreatment for infiltration anesthesia. Lenzetto (estradiol 1.53 mg/spray, transdermal spray, solution) is an estradiol spray for women which is used to treat moderate to severe hot flushes commonly associated with menopause. Testosterone Topical Solution is indicated for replacement therapy in males for conditions associated with a deficiency or absence of endogenous testosterone.
Employees
43
Date Price Change Volume
07/07/26 $0.0115 -4.17% 81,450
06/07/26 $0.0120 0.00% 416,666
03/07/26 $0.0120 0.00% 540,342
02/07/26 $0.0120 -7.69% 3,018,264
01/07/26 $0.0130 +8.33% 815,493

Annual profits - Rate of surprise